Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 105 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Follow-Up Questions
Who is the CEO of Artiva Biotherapeutics Inc?
Dr. Fred Aslan is the President of Artiva Biotherapeutics Inc, joining the firm since 2021.
What is the price performance of ARTV stock?
The current price of ARTV is $4.88, it has decreased 3.15% in the last trading day.
What are the primary business themes or industries for Artiva Biotherapeutics Inc?
Artiva Biotherapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Artiva Biotherapeutics Inc market cap?
Artiva Biotherapeutics Inc's current market cap is $119.2M
Is Artiva Biotherapeutics Inc a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Artiva Biotherapeutics Inc, including 4 strong buy, 7 buy, 1 hold, 0 sell, and 4 strong sell
